{"filing":{"accession_number":"0001193125-26-309012","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"d125683d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526309012/d125683d8k.htm"},"events":[{"id":18851,"run_id":16956,"accession_number":"0001193125-26-309012","anchor_item_number":"1.03","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"Sangamo Therapeutics filed a voluntary petition for Chapter 11 bankruptcy relief on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company is operating as a debtor-in-possession and has obtained court approval for bidding procedures to sell substantially all assets.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17787,"accession_number":"0001193125-26-309012","item_number":"1.03","item_title":"Bankruptcy or Receivership.","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics filed a voluntary petition for Chapter 11 relief on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company is operating as a debtor-in-possession and has obtained court approval for bidding procedures to sell substantially all assets. This is an unmistakable bankruptcy filing disclosure under Item 1.03, representing a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:45:45.050671+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18852,"run_id":16956,"accession_number":"0001193125-26-309012","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The Nasdaq Hearings Panel issued a final delisting determination denying Sangamo's request to continue listing on The Nasdaq Capital Market due to failure to meet the minimum bid price requirement. The company's stock has been suspended from Nasdaq and is now trading on the OTCID Basic Market, with Nasdaq expected to file a Form 25 to delist and deregister the common stock.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17788,"accession_number":"0001193125-26-309012","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a final delisting determination by the Nasdaq Hearings Panel denying the Company's request to continue listing on The Nasdaq Capital Market due to failure to meet the minimum bid price requirement. The Company's stock has already been suspended from Nasdaq (May 5, 2026) and is now trading on OTCID Basic Market. While the Company also filed for Chapter 11 bankruptcy on June 23, 2026, the Item 3.01 disclosure centers on the delisting determination and the Company's expectation that Nasdaq will file a Form 25 to delist and deregister the common stock, making delisting_risk the most precise classification for this section.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:45:45.050671+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17787,"accession_number":"0001193125-26-309012","item_number":"1.03","item_title":"Bankruptcy or Receivership.","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics filed a voluntary petition for Chapter 11 relief on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company is operating as a debtor-in-possession and has obtained court approval for bidding procedures to sell substantially all assets. This is an unmistakable bankruptcy filing disclosure under Item 1.03, representing a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:45:45.050671+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-20"},{"id":17788,"accession_number":"0001193125-26-309012","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a final delisting determination by the Nasdaq Hearings Panel denying the Company's request to continue listing on The Nasdaq Capital Market due to failure to meet the minimum bid price requirement. The Company's stock has already been suspended from Nasdaq (May 5, 2026) and is now trading on OTCID Basic Market. While the Company also filed for Chapter 11 bankruptcy on June 23, 2026, the Item 3.01 disclosure centers on the delisting determination and the Company's expectation that Nasdaq will file a Form 25 to delist and deregister the common stock, making delisting_risk the most precise classification for this section.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:45:45.050671+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-20"}]}